Provisions in the new tax and spending bill passed by the Senate would go even further than the House bill in removing health ...

Under the “One Big Beautiful Bill Act," 10.9 million Americans would lose health insurance by 2034, according to estimates by the Congressional Budget Office.

Breast cancer patients may have inferior recurrence-free survival after neoadjuvant chemotherapy if they are overweight or obese at diagnosis.

Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

Waiting about 9 months or more to rechallenge patients with amivantamab can improve outcomes in patients with colorectal cancer, data suggest.

Cuts that would target states could translate into fewer health services, medical professionals, and even hospitals, especially in rural communities.

Cancer patients receiving immune checkpoint inhibitor (ICI) therapy may experience more severe toxicity and have a greater risk of death if they have recently used proton pump inhibitors (PPIs), ...

Results of a meta-analysis suggest that ctDNA positivity is a “biomarker for poor postoperative recurrence and survival outcomes in NSCLC patients,” researchers wrote.

The FDA has removed the REMS program requirement for currently approved BCMA- and CD19-directed autologous CAR T-cell therapies.

Under the “One Big Beautiful Bill Act,” 10.9 million Americans would lose health insurance by 2034, according to estimates from the Congressional Budget Office.

President Donald Trump’s “One Big Beautiful Bill” cuts federal spending on Medicaid and Affordable Care Act marketplaces by about $1 trillion over a decade, according to the nonpartisan Congressional ...

Breast cancer survivors have a lower risk of Alzheimer's disease than cancer-free control individuals, data suggest.